Axcella Therapeutics to Participate in the SVB Securities' 2023 Global Biopharma Conference
Axcella Therapeutics AXLA, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that CEO Bill Hinshaw will present a company …